INS and type 2 diabetes mellitus: In T2DM patients not adequately controlled with metformin, exenatide showed noninferiority effects on HbA1c in comparison to basal insulin glargine add-on therapy, but a better beta-cell function improvement and weight profile (difference −4.6 kg, P < .0001) [40].